POET Technologies (NASDAQ:POET) Stock

POET Technologies

POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.

POET Technologies Inc

Poet Biorefining LLC

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks.
Efzofitimod was generally safe and well tolerated at all doses.
SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced findings from an interim analysis of eight patients in the ongoing Phase 2 EFZO-CONNECT&#x2122; study evaluating its lead therapeutic candidate, efzofitimod, in patients with limited or diffuse systemic sclerosis (SSc, or scleroderma)-related interstitial lung disease (ILD).

News

ATYR

aTyr Pharma Announces Findings From Interim Analysis Of Eight Patients In Ongoing Phase 2 EFZO-CONNECT Study Evaluating Efzofitimod In SSc-ILD Patients

uprina Holdings (Cayman) Limited (NASDAQ:<a href="https://www.benzinga.com/stock/CUPR#NASDAQ">CUPR</a>) ("CUPR" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that its indirect 49%-owned associate, Cuprina MENA Co. Ltd, had completed the set-up of a laboratory, located in Saudi Arabia, equipped to manufacture the company's MEDIFLY maggot debridement therapy for the treatment of chronic wounds and to supply the therapy across the Middle East and North Africa ("MENA") region.
Cuprina MENA is now working towards obtaining the regulatory approvals, including the Saudi Food and Drug Authority license and ISO 13485 certification, required in order to sell the therapy in the MENA region.
In another development, Cuprina MENA has secured exclusive rights from Biopharm UK Ltd ("BioPharm"), the world's leading provider of medicinal leeches, to sell these leeches across the Gulf Cooperation Council ("GCC") countries.&nbsp;
Medicinal leeches are increasingly used in the GCC to treat diverse medical conditions including venous congestion, which is a buildup of blood in the veins, and to aid in tissue healing and circulation following reconstructive and microsurgery procedures. The leeches are also used to relieve symptoms of osteoarthritis as well as in veterinary surgery, especially to help treat polycythaemia vera, a chronic blood cancer. &nbsp;

Biotech

General

CUPR

Cuprina Holdings Announces It Has Completed the Set-up Of A Laboratory, Located in Saudi Arabia, Equipped To Manufacture The Company's Medifly Maggot Debridement Therapy For Treatment Of chronic Wounds And To Supply The therapy Across The Middle East And North Africa

Collaboration will leverage Rosy Wellness' extensive reach and community of over 250,000 women
Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals
Daré expects to start recording revenue in the 4th quarter this year

DARE

Daré Bioscience Collaborates With Rosy Wellness To Educate And Market DARE To PLAY Sildenafil Cream

If there is one thing Wall Street loves, it is a hot new trend that promises high returns, exclusivity and limited correlation to the stock and bond markets. The latest products? Private Credit, Private REITs (Real Estate Investment Trusts), and anything else that is not traded on a public exchange.
Our firm, <a href="http://lcmcapital.com">LCM Capital Management</a>, wrote an article for Benzinga only a few months ago talking about what is happening "off market" with stocks, <a href="https://www.benzinga.com/general/25/02/44013224/dark-pools-shrouded-exchanges">Dark Pool &#8211; Shrouded Exchanges</a>. &nbsp;These new private alternative investments are raking in billions from institutional clients and now Wall Street wants to bring it to mom-and-pop investors. I recently read an article talking about these becoming an option within your 401(k) plan. After all, it is what investors want, right? I mean who wouldn't want steep fees, questionable liquidity all with risks that are—ultimately—understated. As Jason Zweig recently wrote in the Wall Street Journal, "Hold on to your wallet. Wall Street is gearing up for a sales push that could enrich the middlemen and impoverish you."
If you have read any of our Benzinga articles, you know our firm has a very skeptical take on the financial industry and the products it creates and pushes. We are firm believers in the theory that most investors don't look to buy these products, they have to be sold to the client. The bet is most investors have not reached out to their broker or advisor to inquire about these investments.&nbsp; Yet it would not surprise us that you received a call from someone about buying this investment and if you have not, you will.&nbsp;
Private Credit really started to emerge back when interest rates where near zero (post financial crisis 2007-08) and institutions were desperately looking for ways to earn more on their money. So what did our industry do? They solved the problem by creating a new market, Private Credit. As a result, all of the big players are now piling in, Blackrock, Goldman, State Street, Apollo, Pimco, KKR, Blue Owl, JP Morgan, and others added weekly. This is actually interesting since JP Morgan's CEO, Jamie Damon, was warning anyone who would listen about this new investment being created and how it is not a good thing, but as you might recall, he said the same thing about Bitcoin initially. Massive fees and very little oversight, and throw in the allure of returns 7% &#8211; 10% and non-correlation to the markets you have the perfect product – what could possibly go wrong?
One of the great things for the issuers/sellers of these products is all in the name, "private." Since the holdings don't trade publicly, valuing these investments is left up to the manager. That's like putting the fox in charge of the hen house. Rob Copeland and Maureen Farrell wrote an excellent article in the New York Times online, Wall St is Minting Easy Money from Risky Loans, stating "Because private credit firms don't have to regularly reveal their loans to regulators, they can create their own rules for how to "mark," or value, their portfolios." Hard to underperform when you make the rules and because most of these investments are illiquid, you don't run the risk of a run on the bank.&nbsp; Take Blackstone's private REIT (BREIT), for example. When investors rushed to withdraw funds in 2022, the firm imposed withdrawal limits, leaving many unable to access their cash. These agreements are packed with clauses that let fund managers freeze withdrawals or restrict access whenever markets get rocky—in other words, right when you might need or want your money the most. You didn't know that? Sorry, It was right there in print, buried within the 300+ page prospectus that I am certain your advisor sent you and told you to read.
Do you find it interesting that the CEO's and top executives at these companies are billionaires and Deca-billionaires? Are you?
Private Credit is different from regular bonds or public loans because it means lending money directly to companies. These loans usually come with higher interest rates and fewer rules. It might sound like a great investment: steady returns, access to exclusive markets, and a supposed hedge against stock market chaos. That is why all these firms have been raising record amounts of capital for their private funds. But there is a catch—investors are locking up their money in opaque investments with little control over when or how they can cash out and the risks are truly unknown.
In the late 90's or .com era, there was a stock creation called "blank check" companies. These "companies" did not own or create anything but their intention was, they would eventually figure out what they would be.
In the mid-2000s, big Wall Street banks created yet another product to fill the supposed needs of investors since interest rates were near zero. I think most everyone reading this recalls the subprime mortgage crisis? Wall Street re-packaged and marketed consumer backed mortgages as a low-risk highly-rated financial investment. Many banks had to be bailed out. Once again, what could go wrong?
During Covid, "blank check" companies made a comeback this time under the disguise of a SPAC (Special Purpose Acquisition Company), again not knowing what they would be, but they would buy something and figure it out. Many went out of business or close to it, some succeeded but at least they were public. You at least could see how much money you were losing.
Today, here we are yet again, a few years later. Wall Street is on the prowl with the promise of plenty of money to be made outside the stock and public bond markets. The problem is, you might not be the one making the money. My partner and I have each been in this wonderful business for over 37 years and any time we see a product that only institutions had access to but now is being made available for the non-institutional investors, it typically does not end well. We are sure there are a few very well-run private credit funds but just like in high school, when all of your friends and then friends of friends got word of a party with no parental oversight, well you know how those ended.&nbsp;
Wall Street has a long history of packaging and marketing high-risk products as must-have investments. Private Credit, private REITs, and private equity placements are just the latest iteration.&nbsp; Perhaps they have a place in a portfolio &#8211; institutions with deep pockets and long-term time horizons that can absorb the risks. For everyday investors, the promise of high returns often masks steep fees, liquidity traps, and underappreciated risks.
Before you invest in private markets, ask yourself, are you doing it because it makes sense for your financial plan, or just because it is the latest trend on Wall Street? More often than not, the answer should have you running away.
If you would like a product with high commissions, high management fees, high leverage, high interest rate costs, high incentive fees, illiquid gated/restricted vehicle and distributions a majority of which are taxed as ordinary income along with estimated values, then maybe private credit is for you.
There is a better way!

Bonds

Opinion

Trading Ideas

Real Estate

The Hottest Party On Wall Street Is One You Might Not Want An Invite To

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP&#xAE;) patient selection technology—today announced a research collaboration with the Indiana Biosciences Research Institute (IBRI). The collaboration is aimed primarily at further deepening the Company's mechanistic understanding of the dual mechanism of action of stenoparib.
Stenoparib is a novel, orally available small-molecule inhibitor of PARP1/2 and tankyrase1/2. As such, stenoparib not only impairs DNA repair to selectively kill cancer cells but also inhibits the WNT signaling pathway—a cellular pathway commonly associated with chemoresistance and advanced-stage disease in multiple cancer types. This unique dual activity distinguishes stenoparib as a highly differentiated therapeutic candidate with the potential to address cancers that are resistant to standard-of-care therapies. Under the agreement, IBRI will conduct advanced molecular and cellular studies to clarify the individual and combined contributions of PARP inhibition and WNT pathway modulation to stenoparib's observed anticancer effects.

ALLR

Allarity Therapeutics Announces Research Collaboration With Indiana Biosciences Research Institute To Further Deepen Mechanistic Understanding Of Dual Mechanism Of Action Of Stenoparib

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Dover Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>).
Supporting his view, Dover, on April 24, posted better-than-expected <a href="https://www.benzinga.com/quote/DOV">earnings for the first quarter</a>.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) doesn&#8217;t make any money, Cramer said. &#8220;I just don&#8217;t know if it has the horses.&#8221;
As per the recent news, Arrowhead Pharmaceuticals, on Monday, initiated Phase 1/2a study of ARO-ALK7 for the treatment of obesity.
Cramer said Snowflake Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NASDAQ">SNOW</a>) CEO Sridhar Ramaswamy is &#8220;cerebral, and he's got a real good closing sense, and man, does he ever have momentum.&#8221;
Supporting his view, Snowflake, on May 21, reported first-quarter revenue of $1.04 billion, beating analyst estimates of $1.01 billion. The AI data cloud company reported adjusted earnings of 24 cents per share, beating analyst estimates of 21 cents per share, according to Benzinga Pro.
Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) is &#8220;always a bridesmaid, never a bride,&#8221; Cramer said.
On the earnings front, Fluor, on May 2, posted mixed first-quarter 2025 results, with key metrics surpassing some expectations. Fluor&#8217;s revenue grew 6.6% year-over-year to $3.982 billion, missing the consensus of $4.18 billion. Adjusted EPS improved to 73 cents from 47 cents a year ago, above the consensus of 50 cents.
Price Action:
<ul class="wp-block-list">
<li>Arrowhead Pharmaceuticals shares gained 1.3% to settle at $16.61 on Tuesday.</li>
<li>Snowflake shares fell 0.5% to close at $209.15.</li>
<li>Dover shares gained 1.1% to close at $177.97.</li>
<li>Fluor shares gained 5.4% to settle at $43.39 on Tuesday.</li>
</ul>
Read Next<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">: </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Markets

Media

ARWR

SNOW

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Federal Reserve Governor Lisa Cook has expressed concerns about the path of inflation, cautioning that new tariffs might reverse recent gains and bring uncertainty into future interest rate decisions.
What Happened: Speaking at the Council on Foreign Relations in New York on Tuesday, Cook noted that inflation had cooled in April, with core prices at 2.5% and headline inflation at 2.1% based on the Fed's preferred measure, <a href="https://www.cnbc.com/2025/06/03/fed-governor-lisa-cook-sees-tariffs-raising-inflation-and-complicating-rate-policy.html">reported</a> CNBC. 
However, she said that these improvements may not last once the impact of tariffs makes its way through the economy. "Price increases tied to changes in trade policy may make it difficult to achieve further progress in the near term," she said. 
"The recent post-pandemic experience with high inflation could make firms more willing to raise prices and consumers more likely to expect high inflation to persist," she added.
Cook did not comment directly on President Donald Trump's policies, but stated, "I do not express views on the Administration's policies. But I do study the economic implications, which appear to be increasing the likelihood of both higher inflation and labor-market cooling."
See Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation</a>
Why It Matters: Cook's remarks come days before the Federal Reserve's next policy meeting on June 17-18. "I see the U.S. economy as still being in a solid position, but heightened uncertainty poses risks to both price stability and unemployment," Cook said. "When making decisions, I think it has been valuable to remain a student of economic history."
The wider impact of tariffs could spread beyond prices. Cook warned that they may dampen hiring and wage growth, which complicates the Fed's dual mandate of ensuring stable prices and maximum employment.
For now, however, Cook made no prediction about when the Fed might cut rates. "Current policy is set in a place where I and my colleagues can respond to threats on either side of the Fed's mandate," she said.
Another Federal Reserve Governor, Christopher Waller, <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45714800/feds-christopher-waller-signals-caution-on-rate-cut-amid-tariff-driven-inflation-risks">recently warned</a> that tariffs might cause a short-term spike in prices, while indicating that rate cuts could be possible later in 2025 if trade policies stabilize and the economic outlook improves.
Markets are expecting rate cuts starting in September, as <a href="https://www.benzinga.com/markets/25/05/45610672/market-is-risk-off-chamath-palihapitiya-flags-rising-investor-fear-as-money-market-fund-assets-hit-724-trillion">investor caution grows</a>. Meanwhile, JPMorgan Chase CEO Jamie Dimon has <a href="https://www.benzinga.com/government/regulations/25/05/45561399/jamie-dimon-says-us-is-not-in-a-sweet-spot-flags-stagflation-risk-and-deficit-problems-amid-trump-china-tensions">raised alarms</a> about potential stagflation, citing fiscal deficits and global instability.
Read Next: <a href="https://www.benzinga.com/markets/economic-data/25/06/45758298/april-inflation-print-was-the-last-vestige-of-pre-tariff-impact-feds-goolsbee-says">April Inflation Print Was The &#8216;Last Vestige&#8217; Of Pre-Tariff Impact, Fed&#8217;s Goolsbee Says</a>
Federal Reserve &#x7C; Photo courtesy: RozenskiP / Shutterstock

Government

Fed Governor Lisa Cook Warns Tariffs Could Undermine Inflation Progress And Delay Interest Rate Cuts Amid Rising Economic Uncertainty

Management

AIRE

reAlpha Appoints Mike Logozzo As CEO

<a target="_blank" href="https://www.benzinga.com/fintech" rel="noreferrer noopener">Fintech mortgage lender</a> Beeline Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) announced Wednesday the upcoming launch of a new home equity access product that allows homeowners to convert a portion of their home equity into immediate cash without incurring debt or monthly payments.
Beeline has partnered with a company ("RealCo") co-owned by Beeline's principal shareholder and CEO.
RealCo will issue stablecoins to access capital to purchase equity from homeowners seeking liquidity.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/45064810/exclusive-beeline-breaks-1-billion-barrier-bets-big-on-ai-and-short-term-rental-surge" rel="noreferrer noopener">Beeline Breaks $1 Billion Barrier, Bets Big On AI And Short-Term Rental Surge</a>
RealCo is engaging with Beeline, which will source consumers and provide services. Beeline Title will provide title and escrow services.
The company said this product will be funded through a stablecoin-backed model, offering homeowners a fast and flexible alternative to traditional refinancing or HELOCs.
The hard launch is likely for late July, with beta transactions beginning in June.
The coins will be backed by ownership through a fractional deed on the property. RealCo will acquire minority ownership in homes (up to 49%) as a nominee for the funders who will receive the stablecoins. Homeowners selling equity can opt to receive RealCo-issued stablecoins or U.S. dollars.
Unlike conventional lending products, this is not a loan transaction tied to interest rates or a buy-back obligation, allowing Beeline to generate consistent revenue in any rate environment.
The company expects it would drive faster percentage-based revenue growth than traditional mortgage lenders, and with the fees, it expects to be well-positioned to reach operational profitability beginning in the fourth quarter of 2025.
RealCo will initially launch in approximately ten thousand U.S. zip codes and only enter into equity purchases on homes valued at $1 million.
Nick Liuzza, CEO of Beeline Holdings, said that provided there's equity in the home, RealCo will mint coins at closing, which may then be converted into U.S. dollars.
The stablecoin mechanism becomes the catalyst for funding, and it is secured by property recorded in 1:1 in the blockchain and in the public record, he said.
Participating homeowners will receive cash at closing and will not be required to repay the funds until the property is sold. Upon sale, RealCo, as nominee for the token holders, will receive its pro rata percentage of the net proceeds.
Beeline's existing product suite includes conventional mortgage offerings and a range of non-QM loan programs, many of which are optimized for 1099 earners, self-employed borrowers, and younger homeowners. The company emphasized that this new product is an addition, not a pivot, from its core model.
The product will likely benefit individuals who do not qualify for traditional cash-out refinancing or HELOCs but have meaningful equity. Beeline anticipates additional use cases to emerge as the product rolls out to a broader audience in the months ahead.
Key U.S. home equity lending players included Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), LendingTree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>), and US Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>).
Price Action: At the last check on Wednesday, BLNE shares were trading higher by 11.7% at $0.9880 premarket.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45748544/walmart-leverages-automation-and-ai-to-cut-costs-and-grow-paving-the-way-for-other-retailers-report" target="_blank" rel="noreferrer noopener">Walmart Leverages Automation And AI To Cut Costs And Grow, Paving The Way For Other Retailers: Report</a></li>
</ul>
Photo via Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Market-Moving Exclusives

Exclusives

Tech

ALLY

BLNE

CITZ

DGLY

EZPW

GDOT

TREE

EXCLUSIVE: Beeline Launches Stablecoin-Backed Home Equity Product, Targets Profitability By Late 2025

Wedbush Securities analyst Dan Ives predicts Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) could reach $250 per share within two years if the Trump administration steps back from aggressive tariff policies.
What Happened: &#8220;New all-time highs for tech are on the horizon,&#8221; Ives stated in his recent interview with Schwab Network, emphasizing that reduced trade tensions could unlock significant value for semiconductor stocks. 
The analyst&#8217;s bullish outlook comes as NVIDIA recently reclaimed its position as the <a href="https://www.benzinga.com/markets/tech/25/06/45763363/nvidia-overtakes-microsoft-as-the-worlds-most-valuable-company-with-3-4-trillion-market-cap-as-morgan-stanley-reaffirms-top-pick-status">world&#8217;s most valuable company</a> with a $3.4 trillion market capitalization, surpassing Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
NVIDIA shares closed at $141.22 on Tuesday, representing a 2.80% gain that pushed its market cap to $3.444 trillion, slightly ahead of Microsoft&#8217;s $3.441 trillion valuation. 
The chipmaker&#8217;s stock has gained momentum <a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong">following strong first-quarter earnings</a> that showed revenue of $44.1 billion, marking a 69% year-over-year increase and beating Wall Street&#8217;s consensus estimate of $43.2 billion.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;New all-time highs for tech are on the horizon,&quot; says <a href="https://twitter.com/DivesTech?ref_src=twsrc%5Etfw">@DivesTech</a>. He notes that the &quot;biggest value to <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> is ahead.&quot; He also adds that <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a> can become a $250 stock in the next couple years if the Trump administration takes &quot;steps back&quot; from tariffs. <a href="https://t.co/2RWOXEq6US">pic.twitter.com/2RWOXEq6US</a>
&mdash; Schwab Network (@SchwabNetwork) <a href="https://twitter.com/SchwabNetwork/status/1929623237102633343?ref_src=twsrc%5Etfw">June 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The rally reflects surging demand for NVIDIA&#8217;s AI chips, which power everything from data centers to generative AI platforms. Morgan Stanley has reaffirmed its &#8220;Overweight&#8221; rating on NVIDIA, calling it a &#8220;unique opportunity&#8221; in the semiconductor industry while maintaining it as a top pick <a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45742324/nvidia-stock-seen-as-unique-opportunity-amid-chip-sector-volatility-says-morgan-stanley-we-are-materially-under-shipping-demand">despite broader sector concerns</a>.
Ives&#8217; optimistic view hinges on the Trump administration potentially easing tariff pressures that have created uncertainty in the tech sector, particularly around U.S.-China trade relations.
However, geopolitical tensions remain a key risk factor. NVIDIA&#8217;s cautious forward guidance reflects uncertainties related to Chinese export restrictions and ongoing trade disputes. Despite these challenges, CEO Jensen Huang described demand as &#8220;incredibly strong&#8221; <a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45742324/nvidia-stock-seen-as-unique-opportunity-amid-chip-sector-volatility-says-morgan-stanley-we-are-materially-under-shipping-demand">during the company&#8217;s recent earnings call</a>.
Benzinga's Edge Stock Rankings indicate that Nvidia maintains a strong price trend across the short, medium, and long term. Full <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">performance metrics can be viewed here</a>.
<figure class="wp-block-image aligncenter size-full is-resized"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="884" height="636" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04033715/image-41.png" alt="" class="wp-image-937749" style="width:498px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04033715/image-41.png 884w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04033715/image-41-300x216.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04033715/image-41-768x553.png 768w" sizes="(max-width: 884px) 100vw, 884px" /></a></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45763451/jamie-dimon-said-us-should-buy-bullets-not-bitcoin-cynthia-lummis-says-the-us-military-disagrees-with-him" target="_blank" rel="noreferrer noopener">Jamie Dimon Said US Should Buy Bullets, Not Bitcoin — Cynthia Lummis Says The US Military ‘Disagrees' With Him</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Jack Hong / Shutterstock.com

MSFT

NVDA

Tech Bull Says NVDA Can Be A $250 Stock If Trump Takes A Step Back From Tariffs

Analysts' ratings for First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.29, a high estimate of $28.00, and a low estimate of $19.00. A 4.78% drop is evident in the current average compared to the previous average price target of $23.41. 
<img src="https://www.benzinga.com/files/images/story/2025/1749038467_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive First Watch Restaurant Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Gregory Francfort</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Todd Brooks</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Brian Vaccaro</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$21.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brian Mullan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to First Watch Restaurant Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Watch Restaurant Gr compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for First Watch Restaurant Gr's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of First Watch Restaurant Gr's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FWRG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on First Watch Restaurant Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About First Watch Restaurant Gr</h2>
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
<h3>A Deep Dive into First Watch Restaurant Gr's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: First Watch Restaurant Gr displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 16.41%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -0.29%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): First Watch Restaurant Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.14%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): First Watch Restaurant Gr's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: First Watch Restaurant Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.4.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

FWRG

Analyst Expectations For First Watch Restaurant Gr's Future

Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $85.22, a high estimate of $105.00, and a low estimate of $70.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 15.06%. 
<img src="https://www.benzinga.com/files/images/story/2025/1749038445_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Lumentum Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Simon Leopold</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Simon Leopold</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$82.00</td>
<td>$96.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lumentum Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lumentum Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Lumentum Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Lumentum Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LITE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lumentum Holdings analyst ratings.</a>
<h2>All You Need to Know About Lumentum Holdings</h2>
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
<h3>Unraveling the Financial Story of Lumentum Holdings</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Lumentum Holdings showcased positive performance, achieving a revenue growth rate of 16.02% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -10.37%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Lumentum Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.03%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Lumentum Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.11%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 2.97, Lumentum Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LITE

Deep Dive Into Lumentum Holdings Stock: Analyst Perspectives (9 Ratings)

In the latest quarter, 10 analysts provided ratings for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $37.1, with a high estimate of $65.00 and a low estimate of $22.00. This current average has decreased by 6.08% from the previous average price target of $39.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1749038428_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Hims &amp; Hers Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Jonna Kim</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$30.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$33.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hims &amp; Hers Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hims &amp; Hers Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Hims &amp; Hers Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hims &amp; Hers Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HIMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hims &amp; Hers Health analyst ratings.</a>
<h2>Get to Know Hims &amp; Hers Health Better</h2>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
<h3>Breaking Down Hims &amp; Hers Health's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Hims &amp; Hers Health showcased positive performance, achieving a revenue growth rate of 110.67% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Hims &amp; Hers Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.44%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hims &amp; Hers Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 9.65%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 6.19%, the company showcases effective utilization of assets.
Debt Management: Hims &amp; Hers Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

In the last three months, 30 analysts have published ratings on Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">9</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $238.79, a high estimate of $325.00, and a low estimate of $167.88. Experiencing a 4.64% decline, the current average is now lower than the previous average price target of $250.42. 
<img src="https://www.benzinga.com/files/images/story/2025/1749038418_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Apple by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$217.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Edison Lee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Underperform</td>
<td>$170.62</td>
<td>$167.88</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$263.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Ananda Baruah</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$215.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$173.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Srini Pajjuir</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$256.00</td>
<td>$259.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$245.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Edison Lee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$167.88</td>
<td>$202.33</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$170.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Edison Lee</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$202.33</td>
<td>$202.33</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$300.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$263.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$252.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Apple. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Apple compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Apple's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Apple's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apple analyst ratings.</a>
<h2>Unveiling the Story Behind Apple</h2>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
<h3>Unraveling the Financial Story of Apple</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, Apple showcased positive performance, achieving a revenue growth rate of 5.08% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 25.99%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Apple's ROE stands out, surpassing industry averages. With an impressive ROE of 37.11%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Apple's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 7.34%, the company showcases efficient use of assets and strong financial health.
Debt Management: Apple's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.47, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

Analyst Expectations For Apple's Future

EXCLUSIVE: Beeline Holdings Tells Benzinga Co. Announced The Upcoming Launch Of A New Home Equity Access Product That Allows Homeowners To Convert A Portion Of Their Home Equity Into Immediate Cash Without Incurring Debt Or Monthly Payments

Anthony Scaramucci, the founder of SkyBridge Capital and former White House communications director, has expressed concern over the length of Sam Bankman-Fried's prison sentence, calling the 25-year term excessive despite being personally impacted by the <a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35445270/the-true-cost-of-the-ftx-collapse-how-much-did-sam-bankman-fried-really-make">collapse of FTX</a>.
"Is 25 years too steep of a price? I think it is," Scaramucci said during an <a href="https://x.com/CryptoAmerica_/status/1930068740369994116">interview</a> with Crypto in America. "I think it&#8217;s too steep of a price for what he did."
Bankman-Fried, the founder of cryptocurrency exchange FTX, was sentenced to 25 years in federal prison in March 2024 for orchestrating one of the largest <a href="https://www.benzinga.com/top-stories/25/05/45448569/ftx-to-distribute-over-5b-to-creditors-in-second-round-of-payouts-on-may-30">financial frauds in recent history</a>.
A federal jury had convicted him in November 2023 on seven criminal counts, including wire fraud and conspiracy to commit money laundering. 
Prosecutors alleged he misused billions of dollars in customer deposits to fund speculative investments, political contributions, and luxury real estate purchases.
Scaramucci's comments come as a surprise given his direct involvement as an investor and victim of the FTX scandal. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45755090/donald-trump-jr-says-crypto-was-a-lifeline-after-being-debanked-we-got-into-it-out-of-necessity">Donald Trump Jr. Says Crypto Was A Lifeline After Being Debanked: &#8216;We Got Into It Out Of Necessity&#8217;</a>
"Even though he harmed me, guys, I&#8217;m a victim of his crime," Scaramucci noted. "The guy really hurt my reputation. He hurt my business. I'm still entangled in the goddamn thing, you know?"
Despite the personal damage, Scaramucci stated he does not hold resentment toward Bankman-Fried. 
"But I don&#8217;t have anything other than a bad feeling for Sam. I don&#8217;t have a vengeful feeling for him or anything like that," he added.
While Scaramucci said he would not support a presidential pardon, he did indicate support for a reduced sentence. 
"Commuting his sentence or reducing his sentence would be something that if someone came to me and said, ‘Hey, would you reduce his sentence?' I would say yes," he said.
Bankman-Fried's sentencing followed a high-profile trial that became a defining moment in crypto's legal reckoning in the United States. Once a prominent figure in the digital asset space, Bankman-Fried's downfall sent shockwaves through the industry, eroding investor trust and prompting renewed regulatory scrutiny.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45754151/ai-dominated-venture-capital-in-q1-2025-says-jp-morgan-report">AI Dominated Venture Capital In Q1 2025, Says JP Morgan Report</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Anthony Scaramucci Says Sam Bankman-Fried's 25-Year Sentence Is 'Too Steep'

On June 3, 2025, as a result of an order issued on May 30, 2025, by the United States Court of Appeals for the Ninth Circuit remanding jurisdiction to the United States District Court for the District of Nevada (the "District Court") over the appeal filed by Rimini Street, Inc. (the "Company") in November 2023 regarding the award of attorneys' fees and costs by the District Court to certain subsidiaries of Oracle Corporation (collectively, "Oracle") in Case Number 2:14-cv-01699-MMD-DJA (Rimini II), which case was originally filed by the Company against Oracle in October 2014, the District Court released an "Order on Fees on Remand" dated June 2, 2025, vacating in full its previous order and corresponding judgment dated September 23, 2024, which had awarded Oracle approximately $58.5 million in attorneys' fees and costs in connection with the Rimini II matter.

RMNI

Ninth Circuit Remands Appeal, District Court Vacates $58.5M Fee Award To Oracle In Rimini II Case

Canaccord Genuity analyst Michael Walkley downgrades CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Buy to Hold and raises the price target from $420 to $475.

Downgrades

Price Target

CRWD

Canaccord Genuity Downgrades CrowdStrike Holdings to Hold, Raises Price Target to $475

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy and maintains $4 price target.

QNCX

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $4 Price Target

As previously disclosed, on May 23, 2023, Inotiv, Inc. (the "Company") received a voluntary request from the U.S. Securities and Exchange Commission (the "SEC") seeking documents and information for the period from December 1, 2017 to the present regarding the Company, Envigo Global Services, Inc., and Orient BioResource Center, Inc.'s importation of non-human primates from Asia, including information relating to whether their importation practices complied with the U.S. Foreign Corrupt Practices Act. In March 2024, the SEC provided the Company a formal order of investigation concerning this matter that was dated January 9, 2024, and on April 12, 2024, the SEC provided supplemental document requests to the Company.
On June 2, 2025, the SEC provided notice to the Company, through the Company's external counsel, that the SEC's Division of Enforcement (the "Division") has concluded its investigation and, based on the information available to the Division as of the date of its letter, the Division does not intend to recommend an enforcement action by the SEC against the Company.

Comments

POET Technologies

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL